Single-nucleotide polymorphisms upstream of the interleukin 28B (interferon k3) gene (IL28B) strongly influence treatment efficacy in patients carrying hepatitis C virus (HCV) of genotype 1. In patients receiving 12 or 24 weeks of interferon-ribavirin therapy for infection with genotype 2 or 3 (n 5 341), we found that rs12979860 strikingly determined the first phase of viral elimination (P , .001). In patients treated for 24 weeks, rs12979860 also predicted the rate of sustained virologic response (P 5 .02), especially among those with high baseline HCV RNA levels (P 5 .002) or older than 45 years (P 5 .01). Patients carrying CC rs12979860 had higher baseline HCV RNA levels (P , .001) and did not, when treated for 12 weeks, achieve sustained virologic response more often than those carrying CT rs1297986 or TT rs1297986 . The results indicate that IL28B gene testing may identify patients carrying genotype 2 or 3 who could benefit from extended treatment.
Recent studies have revealed that single-nucleotide polymorphisms (SNPs) upstream the interleukin 28B gene (IL28B) encoding interferon k3 [1, 2] strongly influence the outcome of treatment in patients with chronic hepatitis C virus (HCV) infection [3] [4] [5] [6] . These previous studies have mainly encompassed patients carrying genotype 1 of HCV, and it has remained uncertain to what extent IL28B influences the treatment response in patients infected with other viral genotypes. A previous study including 230 patients infected with HCV genotype 2 or 3 concluded that IL28B-related SNPs did not predict a sustained virologic response (SVR) to therapy [4] . Recently, Mangia et al [7] reported that IL28B polymorphisms significantly influenced SVR in patients who did not achieve rapid virologic response (RVR)-that is, patients who were HCV RNA positive after 4 weeks of treatment.
For the present study, we analyzed rs12979860, an IL28B-related SNP, and the viral decay during the first 12 weeks of therapy in white patients participating in the NORDynamIC phase 4 trial (n 5 345). The focus on viral kinetics and IL28B in patients with genotype 2 and 3 HCV infection may help in clarifying the mechanism by which this genetic polymorphism modulates treatment response and reveal if and how IL28B variation could be of relevance to treatment efficacy in these groups of patients.
METHODS
Patients infected with HCV of genotype 2 or 3 were randomized at baseline to receive either 12 or 24 weeks of therapy with 180 lg of pegylated interferon alfa-2a once weekly and 800 mg daily of oral ribavirin (the NORDynamIC trial) [8] . In contrast to the studies by Mangia et al [7] , short-term treatment was not confined to patients with RVR. Samples from 358 patients (of 383 in the trial) were available for SNP analysis; this study includes the 341 white patients (96%). Patients gave written informed consent to participate in the study, which was approved by the regional ethics committee. All patients were human immunodeficiency virus (HIV) antibody negative.
The IL28B-related SNP rs12979860 [3] was determined in plasma samples by allelic discrimination using Taqman minor groove binding (MGB) probes [9] . The following primers and probes were used: rs12979860 forward, GTGCCTGTC-GTGTACTGAACCA; rs12979860reverse, AGCGCGGAGTG-CAATTCA; probe_C, FAM-CCTGGTTCGCGCCTT-MGB; probe_T, VIC-CCTGGTTCACGCCT-MGB.
HCV RNA levels were quantified using the Cobas Taqman assay (Roche Diagnostics). Response kinetics was assessed using HCV RNA levels on days 0, 3, 7, and 29. The first phase of viral decline was defined as the difference in HCV RNA level between baseline and day 3. The decline rate for the second phase (the slope) was calculated using HCV RNA values from days 3 and 7 for patients who were HCV RNA negative on day 29, and values from days 3, 7, and 29 for the remaining patients.
Group comparison of continuous data was performed by the Kruskal-Wallis test or regression analysis. Group distributions were analyzed by the v2 test or Fischer exact test. Response rates were compared by the v2 test or by logistic regression analyses in which CC, CT, and TT genotypes were given values of 0, 1, and 2, respectively. Multiple linear regression was performed using the second-phase decline rate as the dependent variable and the baseline viremia, HCV RNA level reduction between baseline and day 3, and rs12979860 as independent variables. Multiple linear regression was also used to assess the impact of various baseline factors on treatment response, using HCV RNA level on day 7, HCV RNA level on week 4, and SVR as dependent variables and age, body mass index (BMI), liver fibrosis score, baseline HCV RNA level, and rs12979860 as independent variables. Statistical analyses were performed using Statview software (SAS Institute) and SPSS software (version 18; SPSS).
RESULTS
The baseline characteristics of the patients are shown in Table 1 . The rs12979860 SNP genotype was associated with considerably higher baseline HCV RNA levels among patients carrying CC than among those carrying CT or TT. The decreases in HCV RNA level during the first 4 weeks were significantly influenced by the SNP genotype ( Figure 1A ). The impact was observed already after 3 d of therapy (R 2 5 .36; P , .001), with a more pronounced reduction in patients with the CC genotype ( Figure 1B ). SNP variability was also associated with the second-phase decline of HCV RNA level (R 2 5 .12; P 5 .023) ( Figure 1C ). In multivariate analysis, the secondphase slope tended to be influenced by rs12979860 (P 5 .07), but it was not dependent on the first-phase decline (P 5 .37). After 4 weeks of treatment, the HCV RNA levels had declined by a median of 5.68 log IU/mL in patients carrying CC compared with 4.82 and 4.62 log IU/mL in those carrying CT or TT at rs12979860, respectively (P , .001). Accordingly, the C allele copy number (0, 1, or 2) was associated with RVR (P 5 .03) ( Table 1) .
Genetic variation at rs12979860 was not associated with SVR when compared for all patients or within the group of patients receiving short-term therapy (12 weeks). However, the SVR rate was significantly lower (P 5 .02) among patients carrying TT rs12979860 compared with that among patients with other SNP genotypes in patients who received 24 weeks of treatment (Table 1) . However, for patients who reached RVR, there was no significant impact of SNP genotypes. For patients who did not reach RVR, the SVR rate was higher for patients with the CC genotype (P 5 .04).
Variants of rs12979860 influenced response kinetics independently of age, liver fibrosis score, baseline viremia, or BMI, as revealed by multiple linear regression analysis (P , .001 for HCV RNA level on day 7; P 5 .01 for SVR). The SVR rate was low among patients treated for 12 weeks whose baseline HCV RNA level was .5.6 log IU/mL irrespective of SNP genotypes, but it was higher among those whose baseline HCV RNA level was ,5.6 log IU/mL, in particular in patients with CC or CT genotypes (Table 1 ). The SNP genotype significantly influenced the outcome of 24-week treatment in patients who were either .45 years old or had a baseline HCV RNA of .5.6 log IU/ mL; in these subgroups, SVR was achieved in only 29% and 42%, respectively, of patients with the TT rs12979860 genotype.
Treatment outcome in patients who received at least 80% of the dose of pegylated interferon and ribavirin for at least 80% of the time (per protocol therapy) are shown in Table 1 . SVR rates were slightly higher in adherent patients than in the whole set of patients, and all patients treated according to protocol who had a baseline HCV RNA level of ,5.6 log IU/mL achieved SVR after 12 or 24 weeks of treatment, with the exception of a 57% SVR rate in patients with TT rs12979860 who were treated for 12 weeks.
DISCUSSION
We report that the rs12979860 SNP significantly influenced the early viral elimination during treatment in patients infected with HCV genotype 2 or 3, with a more rapid reduction of plasma HCV RNA level in patients carrying the CC SNP genotype, which has previously been shown to determine a high likelihood of SVR in patients infected with HCV of genotype 1 [3, 5, 6, [10] [11] [12] . The reduction of HCV RNA level during therapy typically follows 2 main phases: a rapid first phase during the initial day or days after onset of treatment and a slower second phase. These phases are assumed to reflect the antiviral efficacy (first phase) and the subsequent elimination of infected hepatocytes (second phase) [13, 14] . In our study, the impact of SNP genotype was observed already after 3 d of therapy (P , .001), thus strongly implying that rs12979860 influences the magnitude of the first-phase response. Although SNP variability was also associated with the second phase of reduction of HCV RNA level (P 5 .023), a multiple regression analysis revealed a stronger impact of SNP variants on the first phase reduction.
Thompson et al [11] reported that in patients infected with HCV of genotype 1, HCV RNA levels declined by a median of 3.8 log IU/mL after 4 weeks among those carrying CC compared with 1.1 log IU/mL in patients carrying TT at rs12979860. In our patients infected with HCV genotype 2 or 3, the corresponding decline was 5.68 log IU/mL for patients with CC and 4.62 log IU/mL for those with TT. These findings indicate that the impact of rs12979860 on viral elimination during therapy is less e By logistic regression (with CC, CT, and TT set to 0, 1, and 2, respectively).
pronounced in patients infected with HCV of genotype 2 or 3 than in patients with genotype 1. The impact of rs12979860 genotypes was reflected by the proportion of patients who achieved RVR (67% of patients with CC compared with 47% of patients with TT at rs12979860; P , .05). These results partly disagree with the report by Mangia et al [7] , who found no impact of rs12979860 on RVR (53%-66% of patients) among Italian patients infected with HCV genotype 2 or 3 [7] .
In agreement with the results presented by Rauch et al [10] , there was no significant impact of rs12979860 on SVR when analyzed for all patients infected with HCV genotype 2 or 3. However, in patients receiving 24 weeks of treatment, the SVR rate was significantly lower among patients carrying TT rs12979860 compared with that among patients with other SNP genotypes (P 5 .02). For patients who reached RVR, there was no impact from SNP, arguably because almost all patients in this group who were given 24 weeks of treatment achieved SVR. On the other hand, SNP was important for patients who did not reach RVR; in this group, 2 (29%) of 7 patients with TT, 29 (59%) of 34 patients with CT, and 17 (74%) of 23 patients with CC achieved SVR after 24 weeks of treatment (P 5 .04). These results are consistent with those reported by Mangia et al [7] that IL28B influenced the treatment outcome in patients who did not achieve RVR, with SVR rates of 29%, 67%, and 87% in patients carrying TT, CT, or CC at rs12979860, respectively. The poor outcome in patients carrying TT rs12979860 in both studies suggests that patients with this SNP genotype may benefit from treatment durations longer than 24 weeks if they do not reach RVR. This appears to be of relevance mainly for patients who fail to adhere to treatment, because the impact of IL28B on SVR did not reach statistical significance for patients treated according to protocol for 24 weeks.
The SVR rates among patients receiving short-term treatment (12 weeks) were not influenced by the rs12979860 SNP, despite its strong impact on the early viral clearance. A similar observation was made in the study by Mangia et al [7] , implying that SNP analysis alone is not helpful in selecting candidates for short-term therapy. This unexpected finding may be partly explained by the significantly higher baseline HCV RNA levels observed in patients carrying the CC genotype in both our study and the study by Mangia et al [7] . Thus, patients with the CC genotype may be less likely to be cured by short-term therapy despite a more favorable virologic response because they have a higher viral load at baseline than those with the CT or TT genotypes.
Although SVR rates among patients with HCV genotype 2 or 3 infection are much better than among patients with genotype 1 infection, a significant number of patients with genotype 2 or 3 infection ('20%-25%) are not cured by interferon-ribavirin [15] . The likelihood of SVR is significantly lower in patients with bridging fibrosis or cirrhosis, higher age, or a high viral load at onset of therapy. Our results imply that a combined assessment of SNP and traditional risk factors may improve prognostication of response, at least in subgroups of patients. For patients .45 years old, the rate of SVR after 24 weeks of treatment was 82% (27 of 33 patients) for patients carrying CC rs12979860 but only 29% (2 of 7 patients) for patients carrying TT rs12979860 . In the group with baseline HCV RNA level ,5.6 log IU/mL, 33 (87%) Figure 1 . A, Mean hepatitis C virus (HCV) RNA level in plasma during the first 12 weeks of interferon-ribavirin therapy in patients carrying CC, CT, or TT genotypes at the rs12979860 single-nucleotide polymorphism. B and C, Impact on the first-phase decline and second-phase decline, respectively, of HCV RNA levels during treatment. Each box displays the median and 25th and 75th percentiles; bars show the 10th and 90th percentiles. ***P , .001 (Kruskal-Wallis test).
of 38 patients treated for 12 weeks achieved SVR if they carried the CC rs12979860 or CT SNP genotypes. These findings imply that short-term treatment (12 weeks) of infection with HCV genotype 2 or 3 may be sufficient for patients with low baseline HCV RNA level and CC rs12979860 or CT rs12979860 SNP genotypes.
In summary, our study demonstrates that IL28B-related variability primarily influences the first-phase kinetics of viral elimination during interferon-ribavirin therapy in patients chronically infected with HCV of genotypes 2 and 3. In addition, the results suggest that SNP assessment might be helpful in deciding the suitable treatment duration in subgroups of patients infected with genotype 2 or 3. 
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